Valuation : Orion Oyj

Market Cap 11.12B 12.93B 10.49B 9.56B 17.87B 1,236B 18.03B 125B 48.09B 627B 48.55B 47.49B 1,991B P/E 2026 *
19.6x
P/E 2027 * 16.6x
Enterprise Value 11.03B 12.82B 10.41B 9.48B 17.72B 1,226B 17.88B 124B 47.7B 622B 48.16B 47.11B 1,975B EV / Sales 2026 *
5.26x
EV / Sales 2027 * 4.54x
Free-Float
90.5%
Yield 2026 *
2.46%
Yield 2027 * 2.74%
1 day-1.01%
1 week-1.99%
Current month-0.51%
1 month-2.96%
3 months+13.22%
6 months+13.22%
Current year+24.68%
1 week 39.4
Extreme 39.4
39.8
1 month 38.6
Extreme 38.6
40.2
Current year 31.6
Extreme 31.6
41
1 year 28.6
Extreme 28.6
41
3 years 15.2
Extreme 15.2
41
5 years 15.2
Extreme 15.2
41
10 years 15.2
Extreme 15.2
41
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-1.99% - - 12.94B
-0.11%-3.16%+48.82%+91.49% 1,002B
-0.27%-4.34%+51.52%+65.89% 644B
+1.63%-2.00%+20.49%+71.12% 443B
-0.63%-3.09%+29.84%+34.59% 343B
+0.43%-14.61%+11.32%+27.26% 262B
+0.93%-3.19%-1.31%+8.41% 245B
-2.25%-13.88%+37.33%+47.43% 212B
-0.90%-5.06%-18.47%-57.75% 199B
-0.58%-4.24%+25.65%+90.54% 181B
Average -0.21%-5.18%+22.80%+42.11% 392.19B
Weighted average by Cap. +0.07%-4.39%+31.98%+57.11%

Financials

2026 *2027 *
Net sales 2.1B 2.44B 1.98B 1.8B 3.37B 233B 3.4B 23.57B 9.07B 118B 9.16B 8.96B 376B 2.37B 2.76B 2.24B 2.04B 3.81B 264B 3.85B 26.67B 10.27B 134B 10.36B 10.14B 425B
Net income 566M 658M 534M 486M 909M 62.91B 918M 6.36B 2.45B 31.91B 2.47B 2.42B 101B 668M 777M 630M 574M 1.07B 74.25B 1.08B 7.51B 2.89B 37.66B 2.92B 2.85B 120B
Net Debt -89.76M -104M -84.69M -77.15M -144M -9.98B -146M -1.01B -388M -5.06B -392M -383M -16.08B -333M -387M -314M -286M -535M -37.02B -540M -3.74B -1.44B -18.77B -1.45B -1.42B -59.63B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change
26-09-10 €39.40 -1.01%
26-09-09 €39.80 +0.51%
26-09-08 €39.60 0.00%
26-09-07 €39.60 -0.50%
26-09-04 €39.80 -1.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
79.00EUR
Average target price
76.67EUR
Spread / Average Target
-2.95%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!